The product is developed based on the research conducted by a group of eminent scientists Mahmoud A. ElSohlya,  Waseem Gula,  Larry A. Walkera, via article ( Tolerability of Δ9-THC-Hemisuccinate in a Suppository Formulation as an Alternative to Capsules )  .Study finds out oral absorption is slow and erratic, and the “first-pass” metabolic effect is high, so that when administered orally, there is a variable peak in Δ9 -THC in plasma ranging from 45 min to a few hours, and an overall systemic bioavailability of about 10% . In addition to these pharmacokinetic considerations, the use of capsules in many of these indications can be limited by nausea, vomiting, or difficulty in swallowing. Alternatives for systemic delivery of CBD + THC based formulations via suppository administration is one of the methodologies.